Search results
Showing 1 to 50 of 71 results for psoriasis
Find out more about NICE technology appraisals advisory committee D members
Lay representatives David Chandler David is chief executive of the Psoriasis and Psoriatic Arthritis Alliance (PAPAA), a UK patient...
Biographies and registered interests for members of the Technology Appraisal Committee A
Secukinumab for treating moderate to severe hidradenitis suppurativa (TA935)
Evidence-based recommendations on secukinumab (Cosentyx) for active moderate to severe hidradenitis suppurativa (acne inversa) in adults.
treatment of malignant pleural mesothelioma (2) 23 November 2007 TA103 Psoriasis - efalizumab and etanercept 27 January 2006 TA104...
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.
Deucravacitinib for treating moderate to severe plaque psoriasis (TA907)
Evidence-based recommendations on deucravacitinib for treating moderate to severe plaque psoriasis in adults.
NICE has developed a medtech innovation briefing (MIB) on digital technologies for the detection of melanoma .
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Secukinumab for treating moderate to severe plaque psoriasis in children and young people (TA734)
Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years.
Bimekizumab for treating moderate to severe plaque psoriasis (TA723)
Evidence-based recommendations on bimekizumab (Bimzelx) for treating moderate to severe plaque psoriasis in adults.
NICE approves first treatment in pilot of new approach to cost-comparison fast track appraisals
As part of the recovery from the COVID-19 pandemic, NICE has been working hard to find new ways to develop and publish guidance affected by the work programme pause in 2020, while also delivering the planned programme for 2021.
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.
This guideline sets out an antimicrobial prescribing strategy for secondary bacterial infection of eczema and covers infection of other common skin conditions. It aims to optimise antibiotic use and reduce antibiotic resistance. The recommendations are for adults, young people and children aged 72 hours and over. They do not cover diagnosis.
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Risankizumab for treating moderate to severe plaque psoriasis (TA596)
Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults.
guidance Certolizumab pegol for treating moderate to severe plaque psoriasis Number TA574 Date issued April 2019 Other details
from guidance Tildrakizumab for treating moderate to severe plaque psoriasis Number TA575 Date issued April 2019 Other details
Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)
Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.
Certolizumab pegol for treating moderate to severe plaque psoriasis (TA574)
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating moderate to severe plaque psoriasis in adults.
generic preference-based measures) in children and young people with severe psoriasis are needed to better inform future cost–utility...
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.
Brodalumab for treating moderate to severe plaque psoriasis (TA511)
Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults.
This quality standard covers interventions to improve the uptake of HIV testing among people who may have undiagnosed HIV. It focuses on increasing testing to reduce undiagnosed infection in people at increased risk of exposure. It describes high-quality care in priority areas for improvement.
View quality statements for QS157Show all sections
Sections for QS157
- Quality statements
- Quality statement 1: Hospitals in areas of high and extremely high HIV prevalence
- Quality statement 2: General practice in areas of high and extremely high HIV prevalence
- Quality statement 3: HIV indicator conditions
- Quality statement 4: Regular HIV testing
- Quality statement 5: People who may have been exposed to HIV
- Update information
- About this quality standard
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.
This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.
View recommendations for CG153Show all sections
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Evidence-based recommendations on certolizumab pegol (Cimzia) and secukinumab (Cosentyx) for treating active psoriatic arthritis in adults.
Ixekizumab for treating moderate to severe plaque psoriasis (TA442)
Evidence-based recommendations on ixekizumab (Taltz) for moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)
Evidence-based recommendations on ustekinumab (Stelara) for treating psoriasis in adults.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)
Evidence-based recommendations on adalimumab (Humira) for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.
disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further...
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
Apremilast for treating moderate to severe plaque psoriasis (TA368)
This guidance has been updated and replaced by NICE technology appraisal guidance 419. Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further...
biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or...